Sotorasib was the first KRAS G12C inhibitor tested clinically in the phase I/II CodeBreaK 100 trial (NCT03600883), which enrolled patients with advanced solid tumors, including NSCLC, who had previously received standard therapies. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.